Table 2.
Immunophenotypical Findings
| Antibody | Case 1 | Case 2 | Case 3 | |||
|---|---|---|---|---|---|---|
| MCL | FL | SLL | FL | SLL | MCL | |
| CD5 | + | − | + | − | + | +/− |
| CD10 | − | + | − | + | − | − |
| CD20 | + | + | + | + | + | + |
| CD21 | − | − (FDC+) | − | − (FDC+) | − | − (FDC+) |
| CD23 | − | − (FDC+) | +/− | − (FDC+) | + | − (FDC+) |
| CD43 | + | − | + | − | + | + |
| IgD | n.e. | n.e. | + | + | −/+ | + |
| κ | − | − | − | − | − | − |
| λ | − | − | − | + | − | + |
| MIB1 | 1–2% | 2–10% | 1–2% | 20–30% | 1–5% | 3–10% |
| bcl-2 | + | + | + | − | + | + |
| cyclin D1 | − | − | − | − | − | + |
| p53 | − | − | − | − | − | − |
| p27 | − | + | + | + | + | − |
Differentially expressed antigens are in bold-face type. FDC, follicular dendritic cells; FL, follicular lymphoma; MCL, mantle cell lymphoma; SLL, small lymphocytic lymphoma; n.e., not evaluable.